The Anti-Migraine Effects of M2000 (β-D-Mannuronic Acid) on a Patient with Rheumatoid Arthritis; As a Case Report

(E-pub Ahead of Print)

Author(s): Mahdi Vojdanian, Hossein Ahmadi, Ahmad Reza Jamshidi, Mahdi Mahmoudi, Farhad Gharibdoost, Anis Barati, Abbas Mirshafiey*.

Journal Name: Current Clinical Pharmacology

Volume 12 , 2017


Background: Rheumatoid arthritis (RA) and migraine are both common disorders which are caused by a faulty immune system and autonomic nervous system dysfunction, respectively. Although current treatment outlook has been shown a great improvement in these two diseases, however many side effects have been reported.

Case Report: We report a case of 43-years-female that has been suffered from rheumatoid arthritis for 3 years with a 6 years history of migraine. She had used different types of medication for both rheumatoid arthritis and migraine but during these 6 years no improvement was observed and even migraine progression in this patient became worse. She was admitted to the hospital for 12 weeks follow up to evaluate the effect of β-D-mannuronic acid (M2000) on her RA disease. During 12 weeks of M2000 therapy RA indices including Disease Activity Score (DAS28), simple disease activity index(SDAI) and C-reactive protein (CRP),erythrocyte sedimentation rate (ESR), rheumatoid factor (RF)), anti-cyclic citrullinated peptide antibodies(anti-CCP) and blood determinants were measured.

Conclusion: A significant improvement was seen after 12 weeks of M2000 therapy in both rheumatoid arthritis and migraine which are considered as inflammatory diseases. Therefore, it might be concluded that M2000 as a novel non-steroidal anti-inflammatory drugs (NSAIDs) with immunosuppressive property is able to treat migraine in addition to its potent efficacy on treatment of rheumatoid arthritis.

Keywords: Mannuronic acid, M2000, Migraine, NSAIDs, Rheumatoid arthritis

Rights & PermissionsPrintExport

Article Details

Year: 2017
(E-pub Ahead of Print)
DOI: 10.2174/1574884712666170605101845
Price: $95

Article Metrics

PDF: 0
PRC: 0